Dianthus Therapeutics, Inc. /DE/ (DNTH) insider trading

By person

33 insiders · 121 transactions

10.8×

Marino Garcia holds 10.8 times base salary in stock. $6.82M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $104.39, the price Common Stock was last bought or sold at on the open market here, on 17 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Garcia Marino

CEO AND PRESIDENT

—

$27.96M (12) scheduled

−$27.96M

65,292

0.1167%

$6.82M

—

Savitz Ryan

EVP, CFO & CBO

—

$14.99M (14) scheduled

−$14.99M

0.0000%

$0.00

—

Randhawa Simrat

EVP, Head of R&D

$52.80K (2)

$15.00M (11) scheduled

−$14.95M

4,000

0.0072%

$417.56K

—

Booth Bruce

Director

$10.00M (1)

$254.42K (1)

+$9.75M

1,250,000

2.23%

$130.49M

—

CARR EDWARD

CHIEF ACCOUNTING OFFICER

—

$5.59M (10) scheduled

−$5.59M

0.0000%

$0.00

—

Veness Adam M

SVP, General Counsel and Sec.

—

$4.63M (5) scheduled

−$4.63M

15,000

0.0268%

$1.57M

—

Third Rock Ventures IV, L.P. entity

10% owner

—

$3.06M (2)

−$3.06M

3,058,204

5.47%

$319.25M

+3,061%

Soteropoulos Paula

Director

—

$2.25M (3) scheduled

−$2.25M

0.0000%

$0.00

—

GARDNER JASON

See Remarks

$6.00K (1)

$1.79M (8)

−$1.79M

651,964

1.17%

$68.06M

−3.3%

Fairmount Funds Management LLC entity

Director

$1.40M (5)

—

+$1.40M

0.0000%

$0.00

—

McGeorge Anne

Director

—

$844.82K (5) scheduled

−$844.82K

0.0000%

$0.00

—

COOKE MICHAEL P.

Chief Scientific Officer

—

$654.33K (14)

−$654.33K

240,523

0.4300%

$25.11M

−16.7%

Read Simon

Director

—

$630.79K (7) scheduled

−$630.79K

0.0000%

$0.00

—

DAVIS JOHN C. JR

See Remarks

—

$508.64K (4) scheduled

−$508.64K

8,304

0.0148%

$866.85K

—

ISACSON CHRISTINA K.

Chief Business Officer

—

$316.64K (3)

−$316.64K

83,786

0.1498%

$8.75M

−16.7%

Atlas Venture Fund X, L.P. entity

10% owner

—

$254.42K (1)

−$254.42K

3,148,399

5.63%

$328.66M

+3,154%

ZDRAVESKI ZORAN

See Remarks

—

$193.45K (2)

−$193.45K

128,009

0.2289%

$13.36M

−5.5%

Scadden David

Director

$99.00K (1)

—

+$99.00K

228,175

0.4079%

$23.82M

+17.9%

Deardorf Caren

Chief Commercial Officer

—

$41.98K (1)

−$41.98K

19,762

0.0353%

$2.06M

—

Beetham Thomas W.

See Remarks

—

$41.07K (1)

−$41.07K

19,897

0.0356%

$2.08M

—

Mahoney Stephen F.

See Remarks

—

$38.60K (1)

−$38.60K

17,264

0.0309%

$1.80M

—

Olson Lisa

See Remarks

—

$38.60K (1)

−$38.60K

14,264

0.0255%

$1.49M

—

Stants Kristen

Chief People Officer

—

$38.60K (1)

−$38.60K

20,264

0.0362%

$2.12M

—

Nichols David Wayne

Chief Technical Officer

—

$38.32K (1)

−$38.32K

14,306

0.0256%

$1.49M

—

Byers Blake

Director

—

3,339,137

5.97%

$348.57M

—

GV 2016 GP, L.L.C.

10% owner

—

3,339,137

5.97%

$348.57M

—

Meng Lei

Director

—

2,717,554

4.86%

$283.69M

+123.2%

MOULDER LEON O JR

Director

—

1,436,745

2.57%

$149.98M

+13.1%

RONNEBERG AMY L

Director

—

593,611

1.06%

$61.97M

—

BONNEY MICHAEL W

Director

—

215,346

0.3850%

$22.48M

+11.3%

Daniel Thomas O

Director

—

101,926

0.1822%

$10.64M

+31.7%

Albers Jeffrey W.

Director

—

4,152

0.0074%

$433.43K

—

Borisy Alexis

Director

—

4,100

0.0073%

$428.00K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

700

$104.39

$73.07K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

1,100

$103.20

$113.52K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

3,501

$102.39

$358.47K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

6,771

$101.37

$686.38K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

7,928

$100.43

$796.21K

Randhawa Simrat

1 Sep 2026

EVP, Head of R&D

Sold after exercise

13,309

$106.74

$1.42M

Randhawa Simrat

1 Sep 2026

EVP, Head of R&D

Sold after exercise

7,215

$106.25

$766.59K

Randhawa Simrat

1 Sep 2026

EVP, Head of R&D

Sold after exercise

2,600

$105.19

$273.49K

Read Simon

19 Aug 2026

Director

Sold after exercise

2,778

$117.55

$326.55K

Veness Adam M

10 Aug 2026

SVP, General Counsel and Sec.

Sold after exercise

16,167

$110.38

$1.78M

Read Simon

10 Aug 2026

Director

Sold after exercise

397

$111.77

$44.37K

Read Simon

10 Aug 2026

Director

Sold after exercise

470

$111.05

$52.19K

Read Simon

10 Aug 2026

Director

Sold after exercise

272

$109.96

$29.91K

Read Simon

10 Aug 2026

Director

Sold after exercise

831

$108.95

$90.54K

Read Simon

10 Aug 2026

Director

Sold after exercise

737

$108.17

$79.72K

Read Simon

10 Aug 2026

Director

Sold after exercise

$107.11

$7.50K

McGeorge Anne

10 Aug 2026

Director

Sold after exercise

700

$111.41

$77.99K

McGeorge Anne

10 Aug 2026

Director

Sold after exercise

1,000

$110.64

$110.64K

McGeorge Anne

10 Aug 2026

Director

Sold after exercise

1,800

$109.30

$196.74K

McGeorge Anne

10 Aug 2026

Director

Sold after exercise

2,800

$108.38

$303.46K

McGeorge Anne

10 Aug 2026

Director

Sold after exercise

1,450

$107.58

$155.99K

Garcia Marino

7 Aug 2026

CEO AND PRESIDENT

Sold after exercise

21,909

$108.72

$2.38M

Garcia Marino

7 Aug 2026

CEO AND PRESIDENT

Sold after exercise

104,091

$107.96

$11.24M

Garcia Marino

7 Aug 2026

CEO AND PRESIDENT

Sold after exercise

800

$110.76

$88.61K

Garcia Marino

7 Aug 2026

CEO AND PRESIDENT

Sold after exercise

2,536

$110.02

$279.01K

Garcia Marino

7 Aug 2026

CEO AND PRESIDENT

Sold after exercise

2,373

$109.10

$258.89K

Garcia Marino

7 Aug 2026

CEO AND PRESIDENT

Sold after exercise

23,907

$108.05

$2.58M

Garcia Marino

7 Aug 2026

CEO AND PRESIDENT

Sold after exercise

10,384

$107.49

$1.12M

Veness Adam M

7 Aug 2026

SVP, General Counsel and Sec.

Sold after exercise

616

$111.18

$68.49K

Veness Adam M

7 Aug 2026

SVP, General Counsel and Sec.

Sold after exercise

3,217

$110.61

$355.83K

Savitz Ryan

9 Jul 2026

EVP, CFO & CBO

Sold after exercise

5,566

$101.97

$567.57K

Savitz Ryan

9 Jul 2026

EVP, CFO & CBO

Sold after exercise

15,329

$101.24

$1.55M

Savitz Ryan

9 Jul 2026

EVP, CFO & CBO

Sold after exercise

10,354

$100.22

$1.04M

Veness Adam M

17 Jun 2026

SVP, General Counsel and Sec.

Sold after exercise

13,229

$81.38

$1.08M

Veness Adam M

17 Jun 2026

SVP, General Counsel and Sec.

Sold after exercise

16,771

$80.34

$1.35M

Randhawa Simrat

1 Jun 2026

EVP, Head of R&D

Sold after exercise

4,159

$91.37

$380.01K

Randhawa Simrat

1 Jun 2026

EVP, Head of R&D

Sold after exercise

16,943

$90.72

$1.54M

Randhawa Simrat

1 Jun 2026

EVP, Head of R&D

Sold after exercise

5,428

$89.72

$487.00K

Soteropoulos Paula

8 May 2026

Director

Sold after exercise

599

$85.47

$51.20K

Savitz Ryan

9 Apr 2026

EVP, CFO & CBO

Sold after exercise

8,224

$89.84

$738.84K

Soteropoulos Paula

31 Mar 2026

Director

Sold after exercise

599

$80.11

$47.99K

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

7,232

$85.54

$618.63K

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

19,469

$84.57

$1.65M

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

59,800

$83.90

$5.02M

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

2,366

$82.84

$196.00K

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

800

$81.36

$65.09K

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

1,485

$80.25

$119.17K

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

21,825

$78.86

$1.72M

Savitz Ryan

31 Mar 2026

EVP, CFO & CBO

Sold after exercise

1,390

$78.33

$108.88K

Soteropoulos Paula

24 Mar 2026

Director

Sold after exercise

27,594

$78.05

$2.15M

Randhawa Simrat

12 Mar 2026

EVP, Head of R&D

Sold after exercise

33,830

$81.48

$2.76M

CARR EDWARD

12 Mar 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

300

$85.53

$25.66K

CARR EDWARD

12 Mar 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

200

$83.38

$16.68K

CARR EDWARD

12 Mar 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

3,865

$82.66

$319.48K

CARR EDWARD

12 Mar 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

23,465

$81.75

$1.92M

CARR EDWARD

12 Mar 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

15,852

$80.71

$1.28M

Garcia Marino

12 Mar 2026

CEO AND PRESIDENT

Sold after exercise

900

$85.53

$76.98K

Garcia Marino

12 Mar 2026

CEO AND PRESIDENT

Sold after exercise

200

$83.38

$16.68K

Garcia Marino

12 Mar 2026

CEO AND PRESIDENT

Sold after exercise

12,796

$82.60

$1.06M

Garcia Marino

12 Mar 2026

CEO AND PRESIDENT

Sold after exercise

65,517

$81.74

$5.36M

Garcia Marino

12 Mar 2026

CEO AND PRESIDENT

Sold after exercise

43,505

$80.69

$3.51M

Savitz Ryan

4 Dec 2025

CFO & CBO

Sold after exercise

20,000

$45.18

$903.60K

Randhawa Simrat

14 Nov 2025

EVP, Head of R&D

Sold after exercise

109,031

$38.14

$4.16M

Randhawa Simrat

13 Nov 2025

EVP, Head of R&D

Sold after exercise

18,576

$37.72

$700.69K

Randhawa Simrat

13 Nov 2025

EVP, Head of R&D

Sold after exercise

42,765

$37.04

$1.58M

Randhawa Simrat

13 Nov 2025

EVP, Head of R&D

Sold after exercise

26,166

$35.80

$936.74K

Savitz Ryan

9 Sep 2025

CFO & CBO

Sold after exercise

20,000

$35.00

$700.00K

DAVIS JOHN C. JR

2 Jan 2020

Chief Medical Officer

Sold after exercise

11,294

$15.04

$169.82K

DAVIS JOHN C. JR

20 Dec 2019

Chief Medical Officer

Sold after exercise

919

$15.00

$13.79K

DAVIS JOHN C. JR

10 Dec 2019

Chief Medical Officer

Sold after exercise

17,055

$15.00

$255.83K

DAVIS JOHN C. JR

9 Dec 2019

Chief Medical Officer

Sold after exercise

4,614

$15.00

$69.21K

Show all 121 transactions →

Dianthus Therapeutics, Inc. /DE/

By person

Individual transactions

What was left out